The effect of oral Ivermectin on Demodex associated blepharitis - Ivermectin for the treatment of blepharitis

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2009-013276-46-GB

Enrollment

Registered

2009-09-17

Start date

2010-02-05

Completion date

Unknown

Last updated

2019-12-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Demodex Follicularum associated anterior blepharitis

Interventions

Trade Name: ivermectin Product Name: ivermectin Pharmaceutical Form: Tablet

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients must be over the age of 30 with diagnosis of anterior blepharitis with CD. Patients must be able to speak fluent English. Patients must be able to give informed consent. Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: Patients aged 30 or less will be excluded. Patients unable to give informed consent will be excluded Patients who cannot speak English fluently will be excluded. Patients who are on current treatment for blepharitis will be excluded.

Design outcomes

Primary

Measure	Time frame
Main Objective: Does Ivermectin reduce the count of Demodex Folliculorum found in the cylindrical dandruff associated with anterior blepharitis;Secondary Objective: Does the ivermectin treatment improves the symptoms associated with the anterior blepharitis?;Primary end point(s): The number of demodex infesting the eyelashes pre and post-treatment.	—

Countries

United Kingdom

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026